Descubre lo que realmente dicen los números — antes que el mercado
Analizar ahora
Sentimiento de noticias
¿Las noticias de hoy son una señal de compra o una alerta?
Analizar ahora
Comprar / Mantener / Vender
¿Comprar, mantener o vender? Obtén el veredicto de la IA ahora.
Analizar ahora
Evaluación de riesgos
Descubre riesgos ocultos antes de que afecten a tu cartera.
Analizar ahora
Valor justo
¿Esta acción está barata, correctamente valorada o sobrevalorada?
Analizar ahora
Últimos análisis de IA sobre Jupiter Neurosciences, Inc. - Common Stock
Sin cotización
28.04.2026 22:04
Cotizaciones actuales de Jupiter Neurosciences, Inc. - Common Stock
Bolsa
Ticker
Moneda
Última operación
Precio
Variación diaria
NASDAQ
JUNS
USD
28.04.2026 22:04
0,36 USD
-0,003 USD
-0,72 %
IEX
JUNS
USD
24.04.2026 15:03
0,39 USD
-
Flotación y Liquidez de las Acciones
Flotación Libre50,52 %
Acciones en Flotación18,33 M
Acciones en Circulación36,28 M
Perfil de la empresa para Jupiter Neurosciences, Inc. - Common Stock Acción
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.
